MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT03888534
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇪🇸Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03870555
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03849690
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03811834
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03748953
- Locations
- 🇨🇳
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shanghai Chang Zheng Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03724916
- Locations
- 🇺🇸
ACRC Studies, Poway, California, United States
🇺🇸North Georgia Rheumatology Group-Duluth, Lawrenceville, Georgia, United States
🇺🇸Southwest Rheumatology Research, LLC, Mesquite, Texas, United States
A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03708211
- Locations
- 🇳🇱
Leiden University Medical Center, Department of Clinical Oncology, Leiden, Zuid-holland, Netherlands
🇳🇱Erasmus MC Cancer Institute, Department of Internal Oncology, Rotterdam, Zuid-holland, Netherlands
🇳🇱Radboud University Medical Center, Department of Medical Oncology, Nijmegen, Gelderland, Netherlands
A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease
- Conditions
- Interventions
- Other: PvP001 placeboDrug: Maximum Feasible Dose (MFD) of PvP002Drug: PvP003 placeboDrug: PvP001 100 mgDrug: Maximum Tolerated Dose (MTD) of PvP001Other: PvP002 placeboDrug: PvP003Drug: PvP003 150 mgDrug: PvP001 300 mgDrug: MTD of PvP001 following 7 days of PPI treatmentDrug: PvP001 600 mgDrug: PvP001 900 mg
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT03701555
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03657160
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
- Conditions
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03544229
- Locations
- 🇺🇸
Spring Gastroenterology Associates - Houston, Houston, Texas, United States
🇺🇸Biopharma Informatic Houston 2, Houston, Texas, United States
🇺🇸Baptist Diabetes Associates Research, Miami, Florida, United States